Allergy Therapeutics (LON:AGY) Hits New 1-Year High – What’s Next?

Allergy Therapeutics plc (LON:AGY)’s share price reached a new 52-week high on Tuesday . The stock traded as high as GBX 8 ($0.10) and last traded at GBX 7.70 ($0.10), with a volume of 230809 shares changing hands. The stock had previously closed at GBX 7.70 ($0.10).

Allergy Therapeutics Price Performance

The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The company’s 50-day moving average price is GBX 6.32 and its 200-day moving average price is GBX 5.32. The company has a market cap of £333.90 million, a P/E ratio of -116.67, a P/E/G ratio of -30.70 and a beta of 1.40.

Allergy Therapeutics (LON:AGY) last released its earnings results on Wednesday, November 6th. The company reported GBX (1.07) (($0.01)) earnings per share (EPS) for the quarter. Allergy Therapeutics had a negative return on equity of 155.90% and a negative net margin of 94.29%. As a group, sell-side analysts predict that Allergy Therapeutics plc will post -2.56 earnings per share for the current fiscal year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.